Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy

被引:131
作者
Chen, Changmai [1 ]
Yang, Zhenjun [1 ]
Tang, Xinjing [1 ]
机构
[1] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
基金
中国国家自然科学基金;
关键词
antisense oligonucleotides; chemical modifications; gene-based therapeutics; gene delivery; nucleic acid drugs; precision medicine; siRNA; IN-VIVO DELIVERY; SMALL INTERFERING RNA; TRIGGERED CHARGE-REVERSAL; VON-WILLEBRAND-FACTOR; ANTISENSE OLIGONUCLEOTIDE; SIRNA DELIVERY; TARGETED DELIVERY; OPEN-LABEL; CELLULAR UPTAKE; MESSENGER-RNA;
D O I
10.1002/med.21479
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Gene-based therapy is one of essential therapeutic strategies for precision medicine through targeting specific genes in specific cells of target tissues. However, there still exist many problems that need to be solved, such as safety, stability, selectivity, delivery, as well as immunity. Currently, the key challenges of gene-based therapy for clinical potential applications are the safe and effective nucleic acid drugs as well as their safe and efficient gene delivery systems. In this review, we first focus on current nucleic acid drugs and their formulation in clinical trials and on the market, including antisense oligonucleotide, siRNA, aptamer, and plasmid nucleic acid drugs. Subsequently, we summarize different chemical modifications of nucleic acid drugs as well as their delivery systems for gene-based therapeutics in vivo based on nucleic acid chemistry and nanotechnology methods.
引用
收藏
页码:829 / 869
页数:41
相关论文
共 183 条
  • [1] Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs
    Abifadel, Marianne
    Elbitar, Sandy
    El Khoury, Petra
    Ghaleb, Youmna
    Chemaly, Melody
    Moussalli, Marie-Line
    Rabes, Jean-Pierre
    Varret, Mathilde
    Boileau, Catherine
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2014, 16 (09)
  • [2] Phenotypic heterogeneity of the endothelium I. Structure, function, and mechanisms
    Aird, William C.
    [J]. CIRCULATION RESEARCH, 2007, 100 (02) : 158 - 173
  • [3] Attacking the genome: emerging siRNA nanocarriers from concept to clinic
    Alabi, Christopher
    Vegas, Arturo
    Anderson, Daniel
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2012, 12 (04) : 427 - 433
  • [4] Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis
    Alam, Md Rowshon
    Dixit, Vidula
    Kang, Hyunmin
    Li, Zi-Bo
    Chen, Xiaoyuan
    Trejo, Joann
    Fisher, Michael
    Juliano, Rudy L.
    [J]. NUCLEIC ACIDS RESEARCH, 2008, 36 (08) : 2764 - 2776
  • [5] Multivalent Cyclic RGD Conjugates for Targeted Delivery of Small Interfering RNA
    Alam, Md Rowshon
    Ming, Xin
    Fisher, Michael
    Lackey, Jeremy G.
    Rajeev, Kallanthottathil G.
    Manoharan, Muthiah
    Juliano, Rudy L.
    [J]. BIOCONJUGATE CHEMISTRY, 2011, 22 (08) : 1673 - 1681
  • [6] Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
    Aleku, Manuela
    Schulz, Petra
    Keil, Oliver
    Santel, Ansgar
    Schaeper, Ute
    Dieckhoff, Britta
    Janke, Oliver
    Endruschat, Jens
    Durieux, Birgit
    Roeder, Nadine
    Loeffler, Kathrin
    Lange, Christian
    Fechtner, Melanie
    Moepert, Kristin
    Fisch, Gerald
    Dames, Sibylle
    Arnold, Wolfgang
    Jochims, Karin
    Giese, Klaus
    Wiedenmann, Bertram
    Scholz, Arne
    Kaufmann, Joerg
    [J]. CANCER RESEARCH, 2008, 68 (23) : 9788 - 9798
  • [7] A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study
    Alvarez, Ronald D.
    Sill, Michael W.
    Davidson, Susan A.
    Muller, Carolyn Y.
    Bender, David P.
    DeBernardo, Robert L.
    Behbakht, Kian
    Huh, Warner K.
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 133 (03) : 433 - 438
  • [8] Diversifying microRNA sequence and function
    Ameres, Stefan L.
    Zamore, Phillip D.
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2013, 14 (08) : 475 - 488
  • [9] Targeting von Willebrand factor as a novel anti-platelet therapy; Application of ARC1779, an Anti-vWF aptamer, against thrombotic risk
    Bae, Ok-Nam
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2012, 35 (10) : 1693 - 1699
  • [10] Immunoprotein-Mediated siRNA Delivery
    Balmer, Nicole
    Berdel, Wolfgang E.
    Baeumer, Sebastian
    [J]. MOLECULAR PHARMACEUTICS, 2017, 14 (05) : 1339 - 1351